Join the 'Casodex' group to help and get support from people like you.

Casodex Blog

Usual 'Hot Flash' Therapies Don't Help Prostate Cancer Patients: Study

Posted 3 Oct 2013 by Drugs.com

THURSDAY, Oct. 3 – Treatments that ease hot flashes in menopausal women are not effective against hot flashes in men undergoing hormone therapy for prostate cancer, a new study finds. Hormone therapy in prostate cancer patients reduces levels of male hormones (androgens) to prevent them from reaching prostate cancer cells and stimulating cancer growth. Hot flashes occur in about 80 percent of prostate cancer patients undergoing hormone therapy. "Changing hormone levels cause hot flashes in both women and men, so we hoped that using soy supplements and/or an antidepressant would help reduce them in men as it does in many women," study author Mara Vitolins, a professor of public health sciences at Wake Forest Baptist Medical Center, said in a center news release. The study included 120 prostate cancer patients, aged 46 to 91, undergoing hormone therapy. They were randomly assigned to ... Read more

Related support groups: Prostate Cancer, Casodex, Bicalutamide, Xtandi, Flutamide, Enzalutamide, Nilandron, Nilutamide, Eulexin

Intermittent Hormone Treatment for Prostate Cancer Not the Best

Posted 3 Apr 2013 by Drugs.com

WEDNESDAY, April 3 – Advanced prostate cancer patients who are given drugs aimed at lowering their testosterone production to slow the spread of tumors don't get much benefit if the drugs are given only intermittently. A large international study suggests that the treatment, called intermittent androgen deprivation therapy, may actually do more harm than good, although the numbers are vague and the regimen may temporarily reduce some side effects. "It's not clear whether there is a benefit to intermittent therapy," said study lead author Dr. Maha Hussain, co-leader of the Prostate Cancer Program at the University of Michigan. However, she added, "in terms of survival, it's not superior." At issue are patients with prostate cancer that has spread to other parts of the body. Their prognosis is typically grim, and as part of their treatment, many receive hormone-therapy drugs aimed at ... Read more

Related support groups: Prostate Cancer, Casodex, Bicalutamide, Xtandi, Flutamide, Enzalutamide, Nilandron, Nilutamide, Eulexin

Cancer Chemotherapy Tied to Slight Rise in Risk for Leukemia

Posted 14 Feb 2013 by Drugs.com

THURSDAY, Feb. 14 – Chemotherapy can be a lifesaver for thousands of cancer patients, but a new study suggests that it might slightly raise the odds for a type of leukemia later in life. Over the past 30 years, the risk for acute myeloid leukemia (AML) has increased for patients who underwent chemotherapy for certain forms of cancer, particularly non-Hodgkin lymphoma, the new study found. On the other hand, the researchers from the U.S. National Cancer Institute said other cancer survivors may have a reduced risk for AML due to a change in chemotherapy agents that occurred decades ago. One expert not connected to the study stressed that cancer patients need to put the findings into perspective. "It's important to realize that the risk of developing acute myeloid leukemia related to prior chemotherapy is small and increases with the number of chemotherapy treatments given over time," ... Read more

Related support groups: Cancer, Provera, Methotrexate, Depo-Provera, Lupron, Accutane, Tamoxifen, Medroxyprogesterone, Arimidex, Lupron Depot, Femara, Gleevec, Fluorouracil, Claravis, Zoladex, Tretinoin, Rituxan, Votrient, Tarceva, Avastin

Taking Breaks From Prostate Cancer Hormone Therapy Seems Safe: Study

Posted 5 Sep 2012 by Drugs.com

WEDNESDAY, Sept. 5 – Stop-and-start hormone-deprivation therapy for localized prostate cancer doesn't shorten overall survival compared to continuous treatments, and yields fewer side effects such as impotence and hot flashes, a large new study suggests. A team of Canadian, British and American researchers found that intermittent hormone treatments – which suppress circulating male hormones such as testosterone that "feed" prostate tumors – don't increase the risk of disease progression. Intermittent treatment also doesn't increase the chances that patients whose prostate-specific antigen (PSA) levels are slowly rising will eventually die from prostate cancer. "There has been a lot of work [in this area] over the last two decades, so we figured there would be an improvement in quality of life and hoping there was no detriment to survival," said study author Dr. Juanita Crook, ... Read more

Related support groups: Lupron, Prostate Cancer, Lupron Depot, Zoladex, Casodex, Zytiga, Lupron Depot 3.75 mg, Eligard, Leuprolide, Degarelix, Trelstar, Lupron Depot-PED, Bicalutamide, Abiraterone, Firmagon, Vantas, Goserelin, Supprelin, Trelstar LA, Flutamide

Hormone Drugs Might Not Raise Heart-Related Deaths in Prostate Patients

Posted 6 Dec 2011 by Drugs.com

TUESDAY, Dec. 6 – Men with prostate cancer who are being treated with hormone therapy do not appear to be at increased risk of dying from heart disease, according to a large new review of evidence. Hormone therapy called "androgen deprivation therapy" is a basic of prostate cancer treatment. Several previous studies found that the therapy might increase the risk of cardiac events or even death from prostate cancer. Growing concern led to a U.S. Food and Drug Administration warning and a consensus statement from multiple medical societies, said Dr. Paul Nguyen. But his new research – an analysis of eight randomized clinical trials of more than 4,000 patients, followed for about a decade – reached a different conclusion. "For the majority of men with aggressive prostate cancer, androgen deprivation therapy was associated with better survival and no increased risk of dying from ... Read more

Related support groups: Prostate Cancer, Casodex, Degarelix, Bicalutamide, Firmagon, Flutamide, Cetrotide, Ganirelix, Abarelix, Antagon, Cetrorelix, Nilandron, Eulexin, Nilutamide, Plenaxis

Cancer Patients Should Ask Doctors to Use Simple Terms

Posted 28 Sep 2011 by Drugs.com

WEDNESDAY, Sept. 28 – Cancer patients are often faced with many difficult-to-understand treatment choices that can have serious side effects and even mean the difference between life and death. That's why it's crucial that patients insist doctors use plain language in explaining the options, advised Angela Fagerlin, an associate professor of internal medicine at the University of Michigan Medical School and a researcher at the U-M Comprehensive Cancer Center. "People are making life and death decisions that may affect their survival and they need to know what they're getting themselves into. Cancer treatments and tests can be serious. Patients need to know what kind of side effects they might experience as a result of the treatment they undergo," Fagerlin said in a university news release. She and her colleagues outlined a number of tips to help patients get the information they need ... Read more

Related support groups: Cancer, Provera, Methotrexate, Breast Cancer, Depo-Provera, Lupron, Accutane, Prostate Cancer, Tamoxifen, Medroxyprogesterone, Arimidex, Lupron Depot, Femara, Gleevec, Fluorouracil, Claravis, Renal Cell Carcinoma, Lung Cancer, Zoladex, Tretinoin

For Some Prostate Cancer Patients, Combo Treatment Improves Survival

Posted 13 Jul 2011 by Drugs.com

WEDNESDAY, July 13 – For men who have prostate cancer that's considered "intermediate risk," radiation plus four months of hormone therapy appears to improve survival, a new study finds. This combination of treatments, however, was not effective in men with either low-risk prostate cancer or advanced disease, the researchers said. Men with high-risk cancer need long-term hormone therapy. The hormone therapy is known as androgen deprivation therapy. It's designed to reduce the levels of male hormones (androgens) in the body, since they can stimulate the growth of prostate cancer cells. "For patients with early, localized cancer of the prostate who were treated with radiation therapy, [by] adding short-term androgen deprivation therapy, we improved their cure rates and increased their chance of living 10 years from 57 percent to 62 percent," said lead researcher Dr. Christopher U. Jones, ... Read more

Related support groups: Lupron, Prostate Cancer, Lupron Depot, Zoladex, Casodex, Lupron Depot 3.75 mg, Eligard, Leuprolide, Degarelix, Bicalutamide, Lupron Depot-PED, Trelstar, Firmagon, Goserelin, Vantas, Trelstar LA, Supprelin, Supprelin LA, Viadur, Triptorelin

Common Prostate Cancer Treatment Linked to Bone Decay

Posted 8 Oct 2010 by Drugs.com

FRIDAY, Oct. 8 – A common prostate cancer treatment called androgen deprivation therapy (ADT) is associated with bone decay, according to a new study. The therapy suppresses or blocks the production of male sex hormones that contribute to the growth of prostate cancer. Currently, about 600,000 prostate cancer patients in the United States are being treated with ADT. In the small 12-month study, Australian researchers examined 26 prostate cancer patients being treated with ADT. The investigators found evidence that the men had "structural decay of cortical (hard outer shell) and trabecular (spongy inner mesh) bone," lead study authors Emma Hamilton and Dr. Mathis Grossmann, of the University of Melbourne, explained in a news release from the Endocrine Society. "Sex steroid deficiency induced by ADT for prostate cancer results in microarchitectural decay. Bone fragility in these men may ... Read more

Related support groups: Lupron, Prostate Cancer, Lupron Depot, Zoladex, Casodex, Lupron Depot 3.75 mg, Eligard, Leuprolide, Degarelix, Bicalutamide, Lupron Depot-PED, Trelstar, Firmagon, Goserelin, Vantas, Supprelin, Trelstar LA, Viadur, Trelstar Depot, Triptorelin

Experts Issue Warning on Prostate Hormone Therapy

Posted 1 Feb 2010 by Drugs.com

MONDAY, Feb. 1 – Men with prostate cancer and the physicians who treat them are being warned that the androgen-deprivation therapy (ADT) commonly used against the malignancy might increase the risk of heart attack and cardiac death. "There is a substantial amount of data demonstrating that ADT adversely affects traditional cardiovascular risk factors, including serum lipoproteins, insulin sensitivity and obesity," according to an advisory published online Feb. 1 in Circulation by a group of experts from the American Heart Association, American Cancer Society and the American Urological Association. The warning is guarded, saying that risks have not been found in all studies. "But we think that physicians treating patients with localized and metastatic prostate cancers as well as patients ought to realize that there are significant risks associated with the use of hormone therapy," said ... Read more

Related support groups: Lupron, Prostate Cancer, Lupron Depot, Zoladex, Casodex, Lupron Depot 3.75 mg, Eligard, Leuprolide, Degarelix, Bicalutamide, Lupron Depot-PED, Goserelin, Vantas, Trelstar LA, Supprelin, Supprelin LA, Viadur, Triptorelin, Flutamide, Trelstar Depot

Heart, Bone Problems May Follow Prostate Cancer Treatment

Posted 27 Apr 2009 by Drugs.com

MONDAY, April 27 – Though proven effective, treating prostate cancer with the testosterone-lowering treatment known as androgen deprivation therapy may raise men's risk for developing bone fractures and fatal cardiovascular disease, a new study suggests. The likelihood of developing either side effect remains low, the researchers noted. But the study shines fresh light on the question of how best to weigh the potential benefits of androgen deprivation therapy (ADT) against the potentially serious complications that can ensue. "It is important to point out that these adverse outcomes due to ADT are all preventable, so it's up to a patient's doctor to be vigilant of changes in either cardiovascular or skeletal health that might develop as a result of the therapy," said the study's lead author, Lockwood Taylor, a doctoral candidate in the division of epidemiology and disease control at ... Read more

Related support groups: Prostate Cancer, Zoladex, Casodex, Eligard, Trelstar Depot, Eulexin, Plenaxis, Nilandron

Ask a Question

Further Information

Related Condition Support Groups

Prostate Cancer

Casodex Patient Information at Drugs.com